Navios Maritime Acquisition (NNA) EPS Estimated At $-0.01; Rigel Pharmaceuticals Has 1.39 Sentiment

January 14, 2018 - By Adrian Erickson

Analysts expect Navios Maritime Acquisition Corporation (NYSE:NNA) to report $-0.01 EPS on February, 8.They anticipate $0.12 EPS change or 109.09% from last quarter’s $0.11 EPS. After having $-0.05 EPS previously, Navios Maritime Acquisition Corporation’s analysts see -80.00% EPS growth. The stock increased 2.80% or $0.03 during the last trading session, reaching $1.1. About 322,221 shares traded. Navios Maritime Acquisition Corporation (NYSE:NNA) has declined 4.17% since January 14, 2017 and is downtrending. It has underperformed by 20.87% the S&P500.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $596.22 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Ratings analysis reveals 100% of Rigel Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Rigel Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $7.0 while the high is $11.0. The stock’s average target of $9 is 121.13% above today’s ($4.07) share price. RIGL was included in 2 notes of analysts from August 30, 2016. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Overweight” rating given on Tuesday, August 30 by Piper Jaffray. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Wednesday, August 31.

Great Point Partners Llc holds 4.5% of its portfolio in Rigel Pharmaceuticals, Inc. for 9.11 million shares. Sio Capital Management Llc owns 1.56 million shares or 2.06% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.76% invested in the company for 2.35 million shares. The California-based Dafna Capital Management Llc has invested 0.7% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 1.10 million shares.

The stock decreased 2.16% or $0.09 during the last trading session, reaching $4.07. About 2.35 million shares traded or 67.34% up from the average. Rigel Pharmaceuticals, Inc. (RIGL) has risen 4.56% since January 14, 2017 and is uptrending. It has underperformed by 12.14% the S&P500.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on March, 6. They expect $-0.13 EPS, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.14 actual EPS reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -7.14% EPS growth.

Among 5 analysts covering Navios Maritime Acquisition (NYSE:NNA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Navios Maritime Acquisition had 10 analyst reports since September 22, 2015 according to SRatingsIntel. Citigroup maintained the shares of NNA in report on Friday, August 19 with “Buy” rating. The rating was maintained by Stifel Nicolaus on Friday, October 27 with “Buy”. The stock of Navios Maritime Acquisition Corporation (NYSE:NNA) earned “Buy” rating by Citigroup on Monday, July 18. On Friday, July 7 the stock rating was maintained by Stifel Nicolaus with “Buy”. The rating was maintained by Stifel Nicolaus on Thursday, November 2 with “Buy”. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 10 report. The firm has “Neutral” rating given on Friday, August 11 by Citigroup. Zacks downgraded Navios Maritime Acquisition Corporation (NYSE:NNA) on Tuesday, September 22 to “Hold” rating. The company was downgraded on Friday, March 11 by Wells Fargo.

Investors sentiment decreased to 0.8 in 2017 Q3. Its down 0.51, from 1.31 in 2017Q2. It dived, as 10 investors sold Navios Maritime Acquisition Corporation shares while 20 reduced holdings. 10 funds opened positions while 14 raised stakes. 26.18 million shares or 0.98% less from 26.44 million shares in 2017Q2 were reported. Schwab Charles Inv Management stated it has 0% in Navios Maritime Acquisition Corporation (NYSE:NNA). 55,305 were accumulated by American Int Grp Inc Inc. The Georgia-based Capital Inv Advsrs Ltd has invested 0% in Navios Maritime Acquisition Corporation (NYSE:NNA). Strs Ohio, a Ohio-based fund reported 369,200 shares. Pinnacle Hldg Ltd Llc reported 11,000 shares. Tower Limited Liability (Trc) owns 1,440 shares for 0% of their portfolio. The California-based Wells Fargo Mn has invested 0% in Navios Maritime Acquisition Corporation (NYSE:NNA). Legal And General Grp Inc Public Limited Company invested in 0% or 12,284 shares. Goldman Sachs Group Inc holds 82,933 shares or 0% of its portfolio. 204,096 are held by Tiaa Cref Invest Mngmt Ltd. State Board Of Administration Of Florida Retirement System reported 27,564 shares. Glenmede Tru Na has 0% invested in Navios Maritime Acquisition Corporation (NYSE:NNA) for 500 shares. California Employees Retirement owns 0% invested in Navios Maritime Acquisition Corporation (NYSE:NNA) for 286,854 shares. New York State Common Retirement Fund has invested 0% of its portfolio in Navios Maritime Acquisition Corporation (NYSE:NNA). Pennsylvania-based Susquehanna Gru Ltd Liability Partnership has invested 0% in Navios Maritime Acquisition Corporation (NYSE:NNA).

Navios Maritime Acquisition Corporation provides marine transportation services worldwide. The company has market cap of $165.37 million. It owns a fleet of crude oil, refined petroleum product, and chemical tankers. It currently has negative earnings. The firm charters its vessels to oil companies, refiners, and large vessel operators under long, medium, and short term charters.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: